Speaker Profile


David R. Dills

Bachelor’s Degree, Environmental Science

Global Regulatory Affairs & Compliance Consultant

David R. Dills, Global Regulatory Affairs & Compliance Consultant currently provides regulatory affairs, compliance and quality consultative services for early-stage and established Class I/II/III device, In Vitro Diagnostics, cosmetics and bio/pharmaceutical manufacturers on the global landscape, and also has an accomplished record with more than 25 years of experience in the areas of Regulatory Affairs, Compliance and Quality Systems. He has been previously employed, with increasing responsibilities by medical device manufacturers and consultancies, including a globally recognized CRO and has worked directly with manufacturers engaged in compliance remediation activities and services involving consent decrees, CIA’s, warning letters, 483 observations, and customer generated compliance events, and prepares for and conducts QS and regulatory audits.

He has been directly involved with constructing, reviewing, and/ or remediating regulatory submissions, including 510(k), PMA, IDE applications, IND, BLA and NDA submissions, preparing Supplements, Amendments, U.S. Agent, works closely with the key stakeholders and Agency/Center Reviewers regarding submission meetings and negotiations; clinical affairs and study submissions; and provides regulatory submissions and post-market project leadership and guidance covering different therapeutic and medical specialties based on classification.

Mr. Dills has a strong background in the interpretation and applicability of FDA regulations, including 21 CFR 210/211, 820 QSR/cGMP, Quality System implementation and compliance requirements, GxP training, leads and directs activities for the registration and approval process and working with Agencies in Asia Pacific, EU and The Americas, including but not limited to FDA, European Medicines Agency–EMA, MHRH, ANVISA, PMDA, MOH, SFDA, TGA, and Health Canada; and defining and executing regulatory compliance, risk mitigation and remediation strategies in response to inspection findings. Additional activities include Pre-FDA Facility Inspections, Mock Audits/Due diligence and assessing state of readiness for Pre-approval inspection (PAI/PMA), proof of management oversight, facilitate and direct efforts for remediation planning and monitoring, and assessment of the critical sub-systems, records and document controls; and strives for reduction of regulatory compliance risk for companies.

Mr. Dills has authored and published validation, regulatory and compliance-related articles, commentaries and technical guides, and is an accomplished global industry presenter. Mr. Dills’ academic degrees include Environmental Science and Biology. He is a former Chair and Co- Chair of ASQ’s Section 1506 and associated with the Biomedical Division, RAPS, AdvaMed, PDA, ISPE, and other industry working groups.

Surviving an FDA Inspection: Understand the Do's and Don'ts and Ground Rules
Surviving an FDA Inspection: Understand the Do's and Don'ts and Ground Rules

Speaker:David R. Dills
Time: 25th May 2017 10:00 AM PDT | 01:00 PM EDT
Duration:75 Minutes
Model : GRC-90127

Thu
25
May 2017

Raw Materials Risk Management in GMP Facilities: Avoiding GMP non-Compliance Due to Raw Material Issues
Raw Materials Risk Management in GMP Facilities: Avoiding GMP non-Compliance Due to Raw Material Issues

Speaker:David R. Dills
Time: 18th May 2017 10:00 AM PDT | 01:00 PM EDT
Duration:60 Minutes
Model : GRC-90138

Thu
18
May 2017

Writing and Enforcing Effective SOPs
Writing and Enforcing Effective SOPs

Speaker:David R. Dills
Time: 12th December 2017 10:00 AM PDT | 01:00 PM EDT
Duration:60 Minutes
Model : GRC-90187

Tue
12
Dec 2017

Social Media and Marketing FDA Regulated Products
Social Media and Marketing FDA Regulated Products

Speaker:David R. Dills
Time: 21st July 2017 10:00 AM PDT | 01:00 PM EDT
Duration:60 Minutes
Model : GRC-90167

Fri
21
Jul 2017

No recorded webinars to list here.
No cd/dvd's available.